Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ARYNTATM safely and effectively. See full prescribing information for ARYNTATM. ARYNTATM (lisdexamfetamine dimesylate) Oral Solution, CII Initial U.S. Approval: 2007
Medication labelWhy this: Advisory · dailymed-prescription
ARYNTA is indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: The use of ARYNTA is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5), Use in Specific Populations (8.4)]. ARYNTA is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of ARYNTA for the treatment of obesity have not been established [see Warnings and Precautions (5.2)].
- generic_name
- lisdexamfetamine dimesylate oral
- product_names
- lisdexamfetamine dimesylate oral
- ndc
- 24338-019, 24338-019-01, 24338-103, 24338-103-01, 24338-160, 24338-160-01, 24338-109, 24338-109-01, 24338-162, 24338-162-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en